|Bid||0.0000 x 2200|
|Ask||0.0000 x 3100|
|Day's range||4.5800 - 4.9100|
|52-week range||2.3000 - 5.7300|
|Beta (5Y monthly)||1.63|
|PE ratio (TTM)||N/A|
|Earnings date||05 Nov 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||12.83|
The company reported positive results from a clinical trial for one of its most promising pipeline candidates.
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Kadmon Holdings (NYSE:KDMN) on Monday, setting a price target of $25, which is approximately 470.78% above the present share price of $4.38.
NEW YORK, March 05, 2020 -- Kadmon Holdings, Inc. (NYSE: KDMN) today provided a business update and reported financial and operational results for the fourth quarter and full.